Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type

British Journal of Cancer

Volumn 81, Issue 8, 1999, Pages 1410-1418

  Vos, C B J ^a   Ter Haar, N T ^a   Rosenberg, C ^a   Peterse, J L ^b   Cleton Jansen, A M ^a   Cornelisse, C J ^a   Van De Vijver, M J ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Amplification; CGH; DCIS; LOH; Southern blot analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICROSATELLITE DNA; PROTEIN BAK;

ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CHROMOSOME 16; CHROMOSOME 16Q; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 8Q; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; SOUTHERN BLOTTING; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

EID: 0032738566     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6693372     Document Type: Article

References (42)

1. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD and Brinster RL (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538
2. Adnane J, Gaudray P, Dionne CA, Crumley G, Jaye M and Schlessinger J (1991) BEK and FLG, two receptors to the members of the FGF family are amplified in subsets of human breast cancers. Oncogene 6: 659-663
3. Aldaz CM, Chen T, Sahin A, Cunningham J and Bondy M (1995) Comparative allelotype of in situ and invasive human breast cancer high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55: 3976-3981
4. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staveren IL, Portengen H and Foekens JA (1992) C-myc amplification is a better prognostic factor than HER 2/neu amplification in primary breast cancer. Cancer Res 52: 1107-1113
5. Berx G, Cleton-Jansen A-M, Nollet F, de Leeuw WJF, van de Vijver MJ, Cornelisse CJ and van Roy F (1995) E-cadherin is a tumour/invasion suppressor gene mulated in human lobular breast cancers. EMBO 14: 6107-6115
6. Berx G, Cleton-Jansen A-M, Strumane K, de Leeuw WJF, Nollet F, Van Roy F and Cornelisse CJ (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truneation mutations throughout its extracellular domain. Oncogene 13: 1919-1925
7. Bobrow LG, Happerfield LC, Gregory WM, Springall RD and Millis RR (1994) The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol II: 199-207
8. Chitemerere M, Andersen TI, Holm R, Karlsen F, Borresen AL and Nesland JM (1996) TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Breast Cancer Res Treat 41: 103-109
9. Cleton-Jansen A-M, Moerland EW, Kuipers-Dijkshoorn NJ, Callen DF, Sutherland GR, Hansen B, Devilee P and Cornelisse CJ (1994) At least two different regions are involved in allelic imbalance on chromosome 16q in breast cancer. Genes Chromosomes Cancer 9: 101-107
10. Coene ED, Schelthout V, Winkler RA, Schelfhout AM, van Roy N, Grooteclacs M, Speleman F and de Potter CR (1997) Amplification units and translocation at chromosome 17q and c erbB2 overexpression in the pathogenesis of breast cancer. Virchows Arch 430: 365-372
11. Devilee P and Cornelisse CJ (1994) Somatic changes in human breast cancer. Biochimica Biophysica Acta 1198: 113-130
12. Done SJ, Ameson NCR, Özçelik H, Redston M and Andrulis IL (1998) p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res 58: 785-789
13. Fujti H, Szumel R, Marsh C, Zhou W and Gabrielson E (1996) Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 56: 5260-5265
14. Gupta PK, Sahota A, Boyadjiev SA, Bye S, Shao C, O'Neill JP, Hunter TC, Albertini RJ, Stambrook PJ and Tischfield JA (1997) High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination. Cancer Res 57: 1188-1193
15. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ and Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol II: 167-180
16. Isola J, de Vries S, Chu L, Ghazvini S and Waldman F (1994) Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin embedded tumour samples. Am J Pathol 145: 1301-1308
17. James LA, Mitchell ELD, Menasce L and Varley JM (1997) Comparative genomic hybridization of ductal carcinoma in situ of the breast: identification of regions of DNA amplificalion and deletion in common with invasive breast carcinoma. Oncogene 14: 1059-1065
18. Kallioniemi A, Kallioniemi OP, Sudar D, et al (1992) Comparative genomic hybridization for molecular cytogonetic analysis of solid tumours. Science 258: 818-821
19. Kallioniemi OP, Kallioniemi A and Piper J (1994) Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumours. Genes Chromosomes Cancer 10: 231-243
20. Kanai Y, Oda T, Tsuda H, Ochiai A and Hirohashi S (1994) Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Japanese Journal of Cancer Research 85: 1035-1039
21. Kuukasjarvi T, Tanner M, Pennanen S, Karhu R, Kallioniemi O P and Isola J (1997) Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol 150: 1465-1471
22. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935
23. Mack L, Kerkvliet N, Doig G and O'Malley FP (1997) Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erbB2, BCL2 and Ki 67. Hum Pathol 28: 974-979.
24. Marchetti A, Bultilta F, Girlando S, Dalla Parma P, Pellegrini S, Fina P, Doglioni C, Bolilacqua G and Barbareshi M (1995) MDM2 alterations and mdm2 protein overexpression in breast carcinomas. J Pathol 175: 31-38.
25. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRC A1. Science 266: 66-71
26. Munn KE, Walker RA, Menasce L and Varley JM (1996) Mutations of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ. Br J Cancer 74: 1578-1585
27. Munn KE, Walker RA, Menasce L and Varley JM (1996) Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast. Br J Cancer 73: 636-639
28. Murphy DS, Hoare SF, Going JJ, Malon EE, George WD, Kaye SB, Brown R, Black DM and Keith WN (1995) Characterazation of extensive genetic alterations in ductal carcinoma in situ hy fluorescence in situ hybridization and molecular analysis. J Nat Cancer Inst 87: 1694-1704
29. Oliner JD, Kinzler KW, Melzer PS, George D and Vogelstein B (1992) Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 358: 80-83
30. Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt MS and Donis-Keller H (1995) Allelotyping of ductal carcinoma in situ of the breast: Deletion of loci 8p. 13q. 16q. 17p and 17q. Cancer Res 55: 3399-3405
31. Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning: a Laboratory Manual. Cold Spring Halbor Laboratory Press: New York
32. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ and Page DL (1997) Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysiz. Hum Pathol 28: 967-973
33. Silverstein MJ, Poller DN, Wansman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P and Slamon DJ (1992) Prognostic classification of breast ductal carcinoma in situ. Lancet 345: 1154-1157
34. Simpson JE, Quan DE, O'Malley F, Odom-Maryon T and Clarke PE (1997) Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 151: 161-168
35. Tavassolli FA (1992) Pathology of the Breast. Appleton & Lange: Norwalk CT
36. Tsuda H, Callen DF, Fukutomi T, Nakamura Y and Hirohashi S (1994) Allele loss on chromosome 16q24.2-ter occurs frequently in breast cancers irrespective of differences in phenotype and extent of the spread. Cancer Res. 54: 513-517
37. Ullrich A, Coussins L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J and Yarden Y (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425
38. Varley JM, Swallow JE, Brammar WJ, Whittaker JL and Walker RA (1987) Alterations to either c-erbB2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1: 423-430
39. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL (1988) Genetic alterations during colorectal tumour development. N Engl J Med 319: 525-532
40. Vos CBJ, Cleton-Jansen A-M, Berx G, de Leeuw WJF, ter Harr NT, Peterse JL, Cornelisse CJ and van de Vijver MJ (1997) E-cadherin inactivation in Iobular carcinoma in situ of the breast: an early event in tumourigenesis. Br J Cancer 76: 1131-1133
41. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T and Toyoshima K (1986) Similarity of protein encoded by the human c erb B2 gene to epidermal growth factor receptor. Nature 319: 230-234
42. Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P and Sastre-Garan X (1994) Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB2 proteins and proliferative activity. Semin Diagn Pathol II: 208-214